BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 17474462)

  • 1. [Immunotherapy with monoclonal antibody of malignant lymphoma].
    Ogura M
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():545-60. PubMed ID: 17474462
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel treatment strategies in follicular lymphoma.
    Buske C; Dreyling H; Unterhalt M; Hiddemann W
    Ann Hematol; 2004; 83 Suppl 1():S72. PubMed ID: 15124680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current immunochemotherapy strategies in follicular lymphoma.
    Giné E; Gutiérrez-García G; López-Guillermo A
    Adv Ther; 2010 Oct; 27(10):704-13. PubMed ID: 20820973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recent progress in the therapeutic strategy for follicular lymphoma and mantle cell lymphoma].
    Ogura M
    Rinsho Ketsueki; 2006 Jun; 47(6):495-512. PubMed ID: 16862978
    [No Abstract]   [Full Text] [Related]  

  • 5. [Milestone in healing fatal indolent lymphoma].
    Krankenpfl J; 2004; 42(3-4):106-7. PubMed ID: 15311904
    [No Abstract]   [Full Text] [Related]  

  • 6. [Recent therapeutic progress in non-Hodgkin lymphoma: focusing on diffuse large B-cell lymphoma and follicular lymphoma].
    Ogura M
    Rinsho Ketsueki; 2008 Oct; 49(10):1434-50. PubMed ID: 18833928
    [No Abstract]   [Full Text] [Related]  

  • 7. [Management of follicular lymphoma].
    Izutsu K
    Rinsho Ketsueki; 2014 Oct; 55(10):1929-36. PubMed ID: 25297757
    [No Abstract]   [Full Text] [Related]  

  • 8. Rituximab plus CHOP for diffuse large-B-cell lymphoma.
    Akhtar S; Maghfoor I
    N Engl J Med; 2002 Jun; 346(23):1830-1; author reply 1830-1. PubMed ID: 12050349
    [No Abstract]   [Full Text] [Related]  

  • 9. CHOP chemotherapy followed by Rituximab consolidation as first line treatment in patients with follicular lymphoma. Long-term follow-up of a phase 2 trial.
    Jäger G; Quehenberger F; Linkesch W; Neumeister P
    Eur J Haematol; 2007 May; 78(5):453-5. PubMed ID: 17419745
    [No Abstract]   [Full Text] [Related]  

  • 10. Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: a phase III randomized clinical trial--Intergroup Collaborative Study.
    Van Oers MH; Hagenbeek A; Van Glabbeke M; Teodorovic I
    Ann Hematol; 2002 Oct; 81(10):553-7. PubMed ID: 12424535
    [No Abstract]   [Full Text] [Related]  

  • 11. Epstein-Barr virus-induced lymphoproliferative disorder after rituximab combined with CHOP therapy.
    Johnston A; Salles G; Espinouse D; Felman P; André P; Berger F; Coiffier B
    Clin Lymphoma Myeloma; 2008 Dec; 8(6):356-8. PubMed ID: 19064401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing new monoclonal antibodies for aggressive lymphoma: a challenging road in the rituximab era.
    Friedberg JW
    Clin Cancer Res; 2004 Aug; 10(16):5297-8. PubMed ID: 15328164
    [No Abstract]   [Full Text] [Related]  

  • 13. Prognostic impact of CD31-positive microvessel density in follicular lymphoma patients treated with immunochemotherapy.
    Taskinen M; Jantunen E; Kosma VM; Bono P; Karjalainen-Lindsberg ML; Leppä S
    Eur J Cancer; 2010 Sep; 46(13):2506-12. PubMed ID: 20630741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. It is follicular... . so, why CHOP?
    Nabhan C
    J Clin Oncol; 2007 Mar; 25(7):915-6; author reply 916-7. PubMed ID: 17327620
    [No Abstract]   [Full Text] [Related]  

  • 15. Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma.
    Miles SA; McGratten M
    J Clin Oncol; 2005 Jan; 23(1):247-8. PubMed ID: 15625386
    [No Abstract]   [Full Text] [Related]  

  • 16. Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma.
    Bermúdez A; Marco F; Conde E; Mazo E; Recio M; Zubizarreta A
    Haematologica; 2000 Aug; 85(8):894-5. PubMed ID: 10942955
    [No Abstract]   [Full Text] [Related]  

  • 17. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.
    Taskinen M; Karjalainen-Lindsberg ML; Nyman H; Eerola LM; Leppä S
    Clin Cancer Res; 2007 Oct; 13(19):5784-9. PubMed ID: 17908969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose therapy for follicular lymphoma revisited: not if, but when?
    Lister TA
    J Clin Oncol; 2003 Nov; 21(21):3894-6. PubMed ID: 14517186
    [No Abstract]   [Full Text] [Related]  

  • 19. [Advances in management of follicular lymphoma].
    Zinzani PL
    Rinsho Ketsueki; 2014 Oct; 55(10):1937-40. PubMed ID: 25297758
    [No Abstract]   [Full Text] [Related]  

  • 20. [Systemic follicular lymphoma with cutaneous manifestations and exclusively cutaneous recurrence].
    Palacios Abufón A; Acebo Mariñas E; Gardeazabal García J; García-Ruiz JC
    Actas Dermosifiliogr; 2012 Apr; 103(3):253-5. PubMed ID: 22093542
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.